Accession Number ADA566405
Title Production and Characterization of a Novel OX40 Ligand for Clinical Use.
Publication Date Aug 2012
Media Count 12p
Personal Author A. D. Weinberg
Abstract The goals of the second year/phase of the DOD funded research, PC073499, have been accomplished. We produced two human versions of the OX40 ligand:trimer:Ig protein. The two protein constructs have different human trimer domains (TRAF2 and Matrillin-4), which confer differing folding patterns within the two-dimension structure of the protein. These two fully human OX40L:Ig fusion proteins were administered to non-human primates to test for in vivo activity. The OX40L:Ig fusion proteins showed potent biologic activity in vivo, but it was clear that the one with the TRAF2 trimer domain was superior. Therefore we are moving forward with OX40L:Ig fusion protein with the TRAF2 trimer domain with the ultimate hope of taking it to clinical trials in patients with prostate cancer.
Keywords Cells(Biology)
Clinical medicine
Clinical trials
Co-stimulation
Histology
Hosts(Biology)
In vivo analysis
Ox40
Potency
Primates
Prostate cancer
Proteins
T lymphocytes
Tissues(Biology)
Tumor immunotherapy


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author Angov (Evelina), Bethesda, MD.
Document Type Technical report
Title Note Final rept. 15 Jul 2008-14 Jul 2012.
NTIS Issue Number 1307
Contract Number W81XWH-08-1-0436

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader